Abstract: A new Aβ-amyloid imaging agent 7-methoxy-2(6-fluoropyridin-3-yl)imidazo［2,1-b］-8-pyridinothiazol (¹⁸F-W372) is synthesized, the non-decay corrected radiochemical yield is （25.3±7.1）% （n=6）, the radiochemical purity is more than 99.5%, and the specific activity is 659-721PBq/mol. Biodistribution of the ¹⁸F-W372 in mice indicates that uptake is high in brain, the brain is （4.36±1.44）%ID/g at 5min, the washout from normal brain is fast, and the brain is （0.54±0.16）%ID/g at 30min post injection. The acute toxicity test of ¹⁸F-W372 proves its safety in clinical use. The cortical/cerebellar specific uptake is higher in AD patients than in controls at 40min after injection of ¹⁸F-W372. ¹⁸F-W372 may have potential as a Aβ-amyloid imaging agent for Alzheimer’s disease.